• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Inhalon Biopharma, Inc.

Monday, June 03, 2024
CP
Respiratory
Inhalon Biopharma is a clinical-stage biotechnology company developing faster-acting, more effective, self-administered inhaled treatments to address the over $40B worldwide unmet need for patients suffering from acute respiratory infections (ARIs), including respiratory syncytial virus (RSV), influenza, HMPV and SARS-CoV-2. Inhalon is using its patented drug delivery platform to revolutionize the treatment of viral respiratory infections. Inhalon’s breakthrough is a muco-trapping technology that directly binds to the virus and physically clears it. Virus trapping results in immediate reduction of viral load and prevents severe infection. Inhalon is the only company with broad issued patents covering inhaled treatment of ARIs with human monoclonal antibodies. Already, current partnerships with USAMRDC, NIH and Celltrion Healthcare have provided validation and funding to advance Inhalon’s proprietary platform.
Inhalon Biopharma, Inc.
Company Website: https://www.inhalon.com/
Lead Product in Development: IN-002 Inhaled Monoclonal Antibody for Respiratory Syncytial Virus (RSV)
Number Of Unlicensed Products (For Which You Are Seeking Partners): 4 Unlicensed assets: IN-003 for Inhaled Monoclonal Antibody for Human Metapneumovirus (preclinical) IN-005 for Inhaled Monoclonal Antibody for Influenza (preclinical) IN-006 Inhaled Monoclonal Antibody for SARS/ COVID 19 (Phase 2) IN-007 Inhaled Monoclonal Antibody for Pan-SARS/ COVID 19 (preclinical)

Company HQ City

Morrisville

Company HQ State

North Carolina

Company HQ Country

United States

CEO/Top Company Official

John Whelan

Development Phase of Primary Product

Phase I
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS